Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1999 1
2004 2
2006 1
2007 1
2008 2
2009 2
2010 4
2011 3
2012 7
2013 7
2014 5
2015 3
2016 5
2017 4
2018 4
2019 3
2020 2
2022 5
2023 4
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer-Härdi U, Caspar CB, Deuster S, Senn M, Winterhalder R, Rochlitz C. Mamot C, et al. Among authors: winterhalder r. Sci Rep. 2023 Mar 6;13(1):3705. doi: 10.1038/s41598-023-30950-z. Sci Rep. 2023. PMID: 36879012 Free PMC article. Clinical Trial.
Rapid switching from levetiracetam to brivaracetam in pharmaco-resistant epilepsy in people with and without intellectual disabilities: a naturalistic case control study.
Watkins LV, Dunstall H, Musicha C, Lawthom C, John K, Bright C, Richings C, Harding K, Moon S, Pape SE, Winterhalder R, Allgar V, Thomas RH, McLean B, Laugharne R, Shankar R. Watkins LV, et al. Among authors: winterhalder r. J Neurol. 2023 Dec;270(12):5889-5902. doi: 10.1007/s00415-023-11959-w. Epub 2023 Aug 23. J Neurol. 2023. PMID: 37610448
Antiangiogenic treatment for multiple CNS hemangioblastomas.
Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M. Riklin C, et al. Among authors: winterhalder r. Onkologie. 2012;35(7-8):443-5. doi: 10.1159/000341075. Epub 2012 Jul 3. Onkologie. 2012. PMID: 22846977 Free article.
Correction to: Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.
Sun JJ, Perera B, Henley W, Angus-Leppan H, Sawhney I, Watkins L, Purandare KN, Eyeoyibo M, Scheepers M, Lines G, Winterhalder R, Ashby S, De Silva R, Miller J, Philpott DE, Ashwin C, Howkins J, Slater H, Medhurst D, Shankar R. Sun JJ, et al. Among authors: winterhalder r. J Neurol. 2022 May;269(5):2761. doi: 10.1007/s00415-022-11012-2. J Neurol. 2022. PMID: 35247093 No abstract available.
57 results